

**Remarks**

After entry of the above amendment, claims 1-26 and 42 will be pending in this application.

Claims 1, 2, 16, 17, and 20 to 22 are original claims.

Claims 3 to 15, 18, 19, and 23 to 26 have been amended.

Claims 27 to 41 have been cancelled without prejudice.

New Claim 42 has been added without introducing new matter. Support for this new claim can be found for example on page 23, lines 9 to 15 and throughout the application.


Claims 3 to 15, 18, 19, and 23 to 26 have been amended merely to remove multiple dependencies.

The specification has been amended to add the "Cross Reference to related application" section showing that this application is claiming priority to an earlier US provisional application.

It is respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: April 20, 2006

  
\_\_\_\_\_  
Lyle W. Spruce, Ph.D.  
Registration No. 53,631

Arena Pharmaceuticals, Inc.  
6166 Nancy Ridge Drive  
San Diego, CA 92121  
Telephone: (858) 453-7200 x1425  
Facsimile: (858) 677-0065